The Neuroendocrine Tumor Research Foundation (NETRF) is the largest private funder of NET research. Since 2005, NETRF has funded $22 million in scientific research to expand the molecular understanding of NETs and help drive personalized treatment options for patients.  To that end, NETRF has issued a 2019 Request for Applications (RFA) for innovative research that increases our basic understanding of these uncommon tumors and leads to the development of more effective therapies. Grants ranging from $100,000 to $1.2 million will support projects over one to four years in the areas of basic, translational, or clinical research.

 The National Cancer Institute's (NCI) Cancer Systems Biology Consortium (CSBC) supports systems biology approaches to cancer research and includes U54 CSBC Research Centers, a U24 CSBC Coordinating Center and, through this FOA, well-defined, discrete and circumscribed U01 Research Projects. CSBC Research Projects are expected to involve interdisciplinary teams of scientists, engineers, and cancer researchers who collaborate to advance our understanding of the mechanisms underlying cancer initiation, progression, and treatment. CSBC Research Projects proposed in response to this Funding Opportunity Announcement must be based upon explicit integration of experimental biology and computational modeling to test and validate novel hypotheses in cancer research. 

The National Cancer Institutes (NCI) Cancer Systems Biology Consortium (CSBC) supports systems biology approaches to cancer research and includes U54 CSBC Research Centers, a U24 CSBC Coordinating Center and, through this FOA, well-defined, discrete and circumscribed U01 Research Projects. CSBC Research Projects are expected to involve interdisciplinary teams of scientists, engineers, and cancer researchers who collaborate to advance our understanding of the mechanisms underlying cancer initiation, progression, and treatment. CSBC Research Projects proposed in response to this Funding Opportunity Announcement must demonstrate explicit integration of experimental biology and computational modeling to test and validate novel hypotheses in cancer research.

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites R21 applications for exploratory/developmental research projects designed to solve specific problems and paradoxes in multiple myeloma (MM) and disparities research identified as the NCI Multiple Myeloma Disparities Provocative Questions (MMD PQs). These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in multiple myeloma research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of multiple myeloma and disparities research that are deemed important but have not received sufficient attention. The FOA includes six Multiple Myeloma PQs that represent diverse fields relevant to multiple myeloma disparities research, but all are framed to inspire interested scientists to conceive new approaches and/or feasible solutions. Each research project (application) proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific MMD PQ selected from the list. Projects proposed to address specific MMD PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged as long as they serve the scientific focus of the specific PQ chosen.

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites R01 applications for research projects designed to solve specific problems and paradoxes in multiple myeloma (MM) and disparities research identified as the NCI Multiple Myeloma Disparities Provocative Questions (MMD PQs). These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in multiple myeloma research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of multiple myeloma and disparities research that are deemed important but have not received sufficient attention. The FOA includes six Multiple Myeloma PQs that represent diverse fields relevant to multiple myeloma disparities research, but all are framed to inspire interested scientists to conceive new approaches and/or feasible solutions. Each research project (application) proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific MMD PQ selected from the list. Projects proposed to address specific MMD PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged as long as they serve the scientific focus of the specific PQ chosen.

Offered by the Damon Runyon Cancer Research Foundation, the Damon Runyon-Rachleff Innovation Award provides support for the next generation of exceptionally creative thinkers with "high-risk/high-reward" ideas that have the potential to significantly impact understanding of and/or approaches to the prevention, diagnosis, and treatment of cancer. The award provides funding to extraordinary early-career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. Research supported by the award must be novel, exceptionally creative, and, if successful, have great potential for high impact in the cancer field. Basic and translational/clinical projects will be considered, as will joint submissions from two collaborators working in different disciplines. 

Offered by the Damon Runyon Cancer Research Foundation, the Damon Runyon-Rachleff Innovation Award provides support for the next generation of exceptionally creative thinkers with "high-risk/high-reward" ideas that have the potential to significantly impact understanding of and/or approaches to the prevention, diagnosis, and treatment of cancer. The award provides funding to extraordinary early-career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. Research supported by the award must be novel, exceptionally creative, and, if successful, have great potential for high impact in the cancer field.

The purpose of this Funding Opportunity Announcement (FOA) is to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce ("de-implement") the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Also listed under R21

BBCR works to advance its mission in four principal ways: supporting academic research institutions as they research tools and techniques that can increase the accuracy of and improve outcomes in biopsies and tumor removal procedures; identifying ways to improve patient outcomes and access; investing in emerging research and researchers; and serving as an active contributor to the culture of access and innovation in cancer care. To that end, BBCR is accepting applications from organizations doing breakthrough research focused on the prevention, treatment, and cures for breast and prostate cancer. Grants ranging between $5,000 and $25,000 will be awarded to teams doing research with the potential to significantly improve cancer prevention, treatment, access to, and, ultimately, a cure for breast and prostate cancer.

rants of up to $150,000 over two years will be awarded in support of projects in one or more of the following areas of lung cancer research: lung cancer biology; prevention and screening for early detection; identification of new biomarkers and the development of targeted therapies; development of more effective and less toxic therapies; supportive measures for people with lung cancer and their families; and quality of care and outcomes research. Through the program, basic, translational, and clinical research will be supported. To be eligible, investigators must be affiliated with a nonprofit academic or research institution and must fall into one of the following categories: students and fellows; young and mid-career investigators with less than ten years' experience since initial faculty appointment; non-tenure track researchers, staff scientists, and clinicians (any number years of experience). Proposals from investigators at U.S.-based and international institutions are eligible apply, regardless of residency/citizenship status.

To that end, CCF is accepting applications for its Global Oncology Young Investigator Award. Through the program, a single grant of up to $50,000 will be awarded to an early-career investigator in support of global oncology research. "Global oncology" as defined by the foundation implies an approach to the practice of oncology that acknowledges the reality of limited resources in most parts of the world. Projects therefore need to be a research exercise - identifying training models, researching their outcomes, analyzing the outcomes of those models to select the most effective curriculum, and/or researching the cost of creating sustainable models where they do not exist.

The Lung Cancer Research Foundation's pilot grant program provides funding for innovative research focused on the prevention, diagnosis, treatment, and cure of lung cancer. Grants of up to $150,000 over two years will be awarded in support of projects in one or more of the following areas of lung cancer research: lung cancer biology; prevention and screening for early detection; identification of new biomarkers and the development of targeted therapies; development of more effective and less toxic therapies; supportive measures for people with lung cancer and their families; and quality of care and outcomes research.

This funding opportunity announcement (FOA) encourages the submission of exploratory/developmental research grant (R21) applications for cancer epidemiologic research. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance population-based cancer research, such as improving data collection methods, developing and validating methods of exposures and biological effects, such as epigenetics and metabolomics, and their application in population-based research, functional assessment of genetic variants, and assessing recruitment methods for understudied populations.

The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are: Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must move beyond a minor advancement and have the potential to lead to a new approach that is fundamentally better than interventions already approved or in clinical development. Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research. Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. It is the responsibility of the Principal Investigator (PI) to select the level that aligns with the scope of the proposed research. The funding level should be selected based on the research scope defined in the Program Announcement, and not on the amount of the budget. An application that does not meet the intent of the funding level selected will not be recommended for funding, even if it might meet the intent of a different funding level.

The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are: Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must move beyond a minor advancement and have the potential to lead to a new approach that is fundamentally better than interventions already approved or in clinical development. Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research. Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. It is the responsibility of the Principal Investigator (PI) to select the level that aligns with the scope of the proposed research. The funding level should be selected based on the research scope defined in the Program Announcement, and not on the amount of the budget. An application that does not meet the intent of the funding level selected will not be recommended for funding, even if it might meet the intent of a different funding level.

The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are: Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must move beyond a minor advancement and have the potential to lead to a new approach that is fundamentally better than interventions already approved or in clinical development. Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research. Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. It is the responsibility of the Principal Investigator (PI) to select the level that aligns with the scope of the proposed research. The funding level should be selected based on the research scope defined in the Program Announcement, and not on the amount of the budget. An application that does not meet the intent of the funding level selected will not be recommended for funding, even if it might meet the intent of a different funding level.

The FY19 PCRP Translational Science Award mechanism supports translational research that will develop promising ideas in prostate cancer into clinical applications. Translational research may be defined as an integration of basic science and clinical observations. Observations that drive a research idea may originate from a laboratory discovery, population-based studies, or a clinician's firsthand knowledge of patient care. The ultimate goal of translational research is to move a concept or observation forward into clinical application. As such, applications must include a detailed transition plan that articulates the pathway to moving the project's findings to the next phase of development after successful completion of the award, and how the Principal Investigator (PI) will continue advancing the research toward making a clinical impact, even if clinical impact is not an immediate outcome. However, PIs should not view translational research as a one-way continuum from bench to bedside. The research plan must involve a reciprocal flow of ideas and information between basic and clinical science. The potential impact of the research is expected to be significant and go beyond an incremental advance. Proposed projects may include basic, translational, population science, and/or clinical research, but must demonstrate clinical relevance.

The Brander Beacons Cancer Research awards grants in the memory of Christopher E. Brander, the inventor of the LOCalizer™ from Health Beacons, a medical device that revolutionized the standard of care for marking breast lesions for surgical removal. BBCR works to advance its mission in four principal ways: supporting academic research institutions as they research tools and techniques that can increase the accuracy of and improve outcomes in biopsies and tumor removal procedures; identifying ways to improve patient outcomes and access; investing in emerging research and researchers; and serving as an active contributor to the culture of access and innovation in cancer care. To that end, BBCR is accepting applications from organizations doing breakthrough research focused on the prevention, treatment, and cures for breast and prostate cancer.

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications from investigators to participate in the HLA and KIR Region Genomics in Immune Mediated Diseases Consortium (HLARGC). This cooperative research group supports projects defining the association between variations in the human leukocyte antigen (HLA), also known as the Major Histocompatibility Complex (MHC), and natural killer cell immunoglobulin-like receptor (KIR) genetic regions and immune-mediated diseases, including outcomes following cell, tissue, and organ transplantation.

The American Association for Cancer Research-Johnson & Johnson Lung Cancer Innovation Science Grants program is a joint effort to address the need for promoting and supporting collaborative cancer research in areas that include digital therapeutics and smoking cessation, as well as biomarkers/behavioral phenotyping that bolster  understanding of how lung cancer can be successfully intercepted.  To that end, a grant of $1 million over three years will be awarded to a multi-institutional team in support of a new idea and/or innovative approach that has direct application and relevance to lung cancer prevention and interception. The proposed research should be translational in nature and include a clinical component with an endpoint relevant to improving the detection or treatment of lung cancer.